Skip to main content
PCI Biotech Holding logo

PCI Biotech Holding — Investor Relations & Filings

Ticker · PCIB ISIN · NO0010405640 LEI · 5967007LIEEXZXFIGG77 OL Manufacturing
Open in API
Filings indexed 752 across all filing types
Latest filing 2024-09-02 Director's Dealing
Country NO Norway
Listing OL PCIB

About PCI Biotech Holding

https://www.pcibiotech.no/

PCI Biotech Holding is a biopharmaceutical company developing therapeutic products based on its proprietary Photochemical Internalization (PCI) technology. This platform is a drug and nucleic acid delivery system designed to enhance the intracellular delivery of therapeutic molecules. The company's development programs are focused on applications in immunotherapy, dermatology, and bioprocessing for the manufacturing of viral vectors. A primary therapeutic area for the technology is cancer, where it aims to improve the efficacy of novel and existing treatments.

Recent filings

Filing Released Lang Actions
PCI Biotech: Employee share option scheme
Director's Dealing Classification · 100% confidence The document details a transaction involving a primary insider (CEO/CFO Ronny Skuggedal) of PCI Biotech Holding ASA. The transaction type is explicitly stated as 'Aksept av aksjeopsjon' (Acceptance of share option) involving 400,000 units at a price of 0 NOK, which is characteristic of the granting or acceptance phase of stock options. This type of filing, reporting personal share transactions by company directors and executives, directly corresponds to the definition of Director's Dealing (DIRS). Although it involves options, the core purpose is reporting insider trading activity.
2024-09-02 Norwegian
PCI Biotech: Employee share option scheme
Share Issue/Capital Change Classification · 95% confidence The document announces the granting of share options to key employees and primary insiders, detailing the terms (strike price, vesting conditions, number of options). This directly relates to executive compensation and insider transactions regarding company stock. While it mentions remuneration policy (related to DEF 14A) and insider notifications (related to DIRS), the core subject is the issuance of options to employees/insiders, which falls under the scope of insider dealing/director's dealings (DIRS) or potentially a general capital/financing update (CAP) or remuneration disclosure (DEF 14A). Since it specifically details transactions by primary insiders (CEO/CFO, CSO) and mentions that 'Primary insider notifications pursuant to the market abuse regulation article 19 are attached,' the most precise classification is Director's Dealing (DIRS), as this covers personal share transactions by executives/insiders, which stock options fall under. It is not a full remuneration report (DEF 14A) or a general capital change (SHA). Given the focus on insider transactions, DIRS is the best fit.
2024-09-02 English
PCI Biotech first half 2024 interim results
Investor Presentation Classification · 95% confidence The document is titled 'PCI Biotech - First half-year 2024 Interim Report' and is explicitly described as a presentation dated August 28, 2024. It contains operational reviews, R&D milestones, and key financial figures for the first half of 2024. While it contains financial data, the format is clearly a slide deck presentation intended for investors, rather than a formal statutory interim financial report. Therefore, it is classified as an Investor Presentation. H1 2024
2024-08-28 English
PCI Biotech first half 2024 interim results
Interim / Quarterly Report Classification · 100% confidence The document is titled '2024 FIRST HALF-YEAR INTERIM REPORT' and contains comprehensive financial statements, including an income statement, cash flow, and balance sheet for the period ending June 30, 2024. It provides detailed operational reviews and financial analysis, fitting the definition of an Interim/Quarterly Report (IR). H1 2024
2024-08-28 English
PCI Biotech first half 2024 interim results
Report Publication Announcement Classification · 99% confidence The document explicitly announces the "PCI Biotech first half 2024 interim results." It mentions that the "interim report and presentation" are enclosed/available. This content describes a comprehensive financial report for a period shorter than a year (half-year results). This directly corresponds to the definition of an Interim / Quarterly Report (Code: IR). Although it mentions the report is enclosed, the primary focus and content provided are the results summary and operational highlights, making it more than just a simple announcement of publication (RPA).
2024-08-28 English
PCI Biotech: Invitation to first half interim 2024 results presentation
Report Publication Announcement Classification · 98% confidence The document is an invitation to a webcast presentation for the company's 'first half 2024 interim report'. It explicitly states that the interim report and presentation will be made available on a specific date and time. Since the document itself is an announcement about the publication and presentation of a report, rather than the comprehensive report (Interim Report/IR) or the presentation itself (IP), it fits the definition of a Report Publication Announcement (RPA). The document length (2633 chars) is short, supporting the RPA classification based on the 'MENU VS MEAL' rule.
2024-08-23 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.